股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01112 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD 100, ...

Core Insights - The Chinese health food industry is experiencing a structural transformation characterized by "inventory reshuffling and weakened growth," moving away from the era of broad-based growth due to regulatory upgrades and evolving consumer concepts [2][10] Industry Overview - In the first half of 2025, the online market for health food reached a sales figure of 60.41 billion yuan, with a year-on-year growth rate of 16.2%, indicating the sector's competitive intensity [2] - Major companies are facing declining revenues, with inventory turnover days increasing, signaling a challenging environment for traditional growth models [2][10] Company Performance - The vitality ranking of health food companies shows significant performance disparities, with innovative companies gaining a premium [4][5] - Key players like健合集团 reported a revenue of 7.02 billion yuan, with a 71.7% increase in revenue from emerging Asian markets, highlighting successful global strategies [5] - 仙乐健康, a leading CDMO, achieved a revenue of 2.042 billion yuan (+2.57%), with a remarkable 200% growth in private traffic contributing to its success [7] - 汤臣倍健's second-quarter net profit grew by 71.4%, indicating effective inventory management and operational efficiency [9] Market Trends - The health food sector is witnessing structural growth, with significant differentiation in performance across companies and product categories [5] - Categories such as cardiovascular health (37.4% growth), bone health (34.9% growth), and women's health (26.0% growth) are emerging as key growth drivers [10] - The shift towards new consumption channels, including live streaming and private domains, is becoming crucial for enhancing customer loyalty and combating rising public traffic costs [10][13] Future Outlook - The industry is expected to continue its trend of differentiation, with a focus on precision, technology, and globalization as core competitive strategies [10][12] - Companies are encouraged to explore overseas markets, particularly in Southeast Asia and Latin America, to leverage demographic advantages and growth potential [13] - The competition is entering a new phase centered on quality improvement, with long-term strategic focus and technological accumulation being vital for success [13]

Group 1 - The core viewpoint of the report is that the functional food industry in China is undergoing a significant transformation driven by rising health awareness and changing consumer demands, leading to accelerated market penetration across all age groups [1][2][11]. - The functional food market in China has experienced a compound annual growth rate (CAGR) of 6.3% over the past five years, significantly outpacing the growth of other basic consumer goods, with the market size expected to exceed 260 billion yuan in 2024 and potentially double to around 450 billion yuan in the next decade [2][22][20]. - The demand for functional foods is shifting from a focus on basic health benefits to a broader appeal that includes emotional satisfaction and lifestyle enhancement, with a diverse range of products catering to various demographics, including women, youth, and even pets [3][27][28]. Group 2 - The growth of the functional food industry is supported by multiple factors, including economic stability, rising disposable income, and an aging population, which has led to increased health consciousness among consumers [2][20][11]. - The online sales channel for functional foods has surged, accounting for over 55% of total sales, with platforms like Douyin (TikTok) and cross-border e-commerce showing remarkable growth, indicating a shift towards digital and diversified sales strategies [5][11][12]. - The industry is characterized by a dual structure of established leading brands maintaining stable market shares while new, agile brands rapidly emerge by capturing niche demands, resulting in a long-tail market trend [6][12][11]. Group 3 - Innovations in product forms and consumer experiences are crucial, with a rise in "snack-like" products such as gummies and beverages that appeal to younger consumers, enhancing the overall consumption experience [4][33][38]. - Marketing strategies are evolving to emphasize emotional resonance and lifestyle alignment, with brands focusing on customized nutrition solutions and appealing packaging to attract younger demographics [4][38][39]. - The report highlights the importance of understanding the changing dynamics in both consumer preferences and distribution channels, suggesting that brands must adapt to these trends to thrive in the competitive landscape [5][12][11].

Core Viewpoint - Several brokerage firms have raised the target price for Jianhe Group, indicating a positive outlook despite overall demand pressure in the maternal and infant industry [1] Financial Performance - Jianhe Group achieved revenue of 7.02 billion RMB in the first half of the year, a year-on-year increase of 5.2% [1] - The infant nutrition (BNC) segment generated revenue of 2.501 billion RMB, growing by 12.5%, with sales of formula milk in mainland China increasing by 10.0%, significantly higher than the industry average growth of 0.2% [1] - The overall gross margin for Jianhe Group in the first half of 2025 was 62.5%, with a net cash flow of 999.8 million RMB and an adjusted comparable net profit of 363 million RMB, maintaining a net profit margin of 5.2% [5] Competitive Advantage - Jianhe Group's competitive edge stems from a complete chain of "raw materials - processes - research," ensuring product quality and brand loyalty [2] - The company sources its core milk supply from high-quality farms in Normandy, France, and utilizes advanced production techniques from the century-old French dairy company Isigny Sainte-Mere [2] - Jianhe Group has established the Jianhe Nutrition and Care Research Institute (BINC) over a decade ago, collaborating with 60 renowned research institutions to advance research in maternal and infant health [2] Channel Strategy - The company's channel strategy emphasizes long-term stable partnerships, providing consistent product quality and pricing to avoid price wars [3] - Jianhe Group enhances its relationship with channel partners through training, co-creation of educational content, and public welfare projects, fostering a strong bond beyond mere supply relationships [4] Market Positioning - The maternal and infant industry has high entry barriers, but once trust is established, partnerships tend to be strong and long-lasting [4] - Jianhe Group's online strategy includes leveraging social media for brand awareness and expert endorsements, leading to effective conversion through e-commerce channels [4] Future Outlook - The "professionalism + long-termism" business model of Jianhe Group is expected to continue strengthening its valuation anchor, with key indicators for future observation including the conversion of research results, changes in high-end market share, and improvements in channel efficiency [5][6]

Core Viewpoint - Several brokerage firms have raised the target price for Jianhe Group, indicating a positive outlook despite overall demand pressure in the maternal and infant industry [1] Financial Performance - Jianhe Group achieved revenue of 7.02 billion RMB in the first half of the year, a year-on-year increase of 5.2% [1] - The infant nutrition (BNC) segment generated revenue of 2.501 billion RMB, growing by 12.5%, with sales of formula milk in mainland China increasing by 10.0%, significantly above the industry average growth of 0.2% [1] - The overall gross margin for Jianhe Group in the first half of 2025 was 62.5%, with a net cash flow of 999.8 million RMB and an adjusted comparable net profit of 363 million RMB, maintaining a net profit margin of 5.2% [5] Competitive Advantage - Jianhe Group's competitive edge stems from a complete chain of "raw materials - processes - research," ensuring product quality and brand loyalty [2] - The company sources its core milk supply from high-quality farms in Normandy, France, and utilizes advanced production techniques from the century-old French dairy company Isigny Sainte-Mere [2] - Jianhe Group has established the Jianhe Nutrition and Care Research Institute (BINC) over a decade ago, collaborating with 60 renowned research institutions to advance research in maternal and infant health [2] Channel Strategy - The company's channel strategy emphasizes long-term stable partnerships, providing consistent product quality and pricing to avoid price wars [3] - Jianhe Group enhances its relationship with channel partners through training, co-creation of educational content, and public welfare projects, fostering a strong bond beyond mere supply relationships [4] Market Positioning - The maternal and infant industry has high entry barriers, but once trust is established, partnerships tend to be strong and long-lasting [4] - Jianhe Group has excelled in online marketing through social media and expert endorsements, leading to significant sales growth during promotional events [4] Future Outlook - The "professionalism + long-termism" business model of Jianhe Group is expected to continue strengthening its valuation anchor, with key indicators for future observation including the conversion of research results, changes in high-end market share, and improvements in channel efficiency [5][6]

Core Viewpoint - H&H International Holdings (01112) reported a 5% year-on-year increase in total revenue for H1 2025, amounting to 7.019 billion yuan, with adjusted comparable EBITDA decreasing by 3% to 1.101 billion yuan, and adjusted comparable net profit increasing by 5% to 363 million yuan. The company is expected to see EPS of 0.79, 1.05, and 1.30 yuan for 2025-2027, with a "Buy" investment rating assigned by Huaxin Securities [1]. Revenue and Profitability - The company experienced a year-on-year revenue increase, with a notable improvement in gross margin. The gross margin for H1 2025 rose by 2 percentage points to 62.53%, driven by higher margins in adult and pet nutrition and care products, along with product mix optimization [1]. - The proportion of sales and distribution/administrative expenses relative to revenue increased by 3 percentage points and decreased by 0.4 percentage points to 42.33% and 5.68%, respectively, due to changes in the channel mix for adult nutrition and care products in mainland China and investments in new market expansion strategies [1]. - Adjusted comparable EBITDA margin and adjusted comparable net profit margin decreased by 1 percentage point and 0.02 percentage points to 15.68% and 5.17%, respectively, primarily due to high base effects from the previous year and increased selling expenses [1]. Business Segment Performance - The adult nutrition and care products segment saw a 5% year-on-year revenue increase to 3.439 billion yuan, largely attributed to the outstanding performance of Swisse's innovative anti-aging product line, which grew by 39% compared to the benchmark [2]. - Revenue from infant nutrition and care products increased by 3% year-on-year to 2.501 billion yuan, driven by effective e-commerce channel development and new mother education initiatives in specialty stores. The company successfully transitioned its products to meet new national standards, with the market share of its premium infant formula brand reaching a historical high of 15.9% [2]. - The pet nutrition and care products segment experienced a 10% year-on-year revenue increase to 1.079 billion yuan, with gross margin rising by 12 percentage points to 58.70%. This growth was supported by deepened partnerships in North America and the ongoing high-end upgrade of Solid Gold in mainland China, leading to significant improvements in profitability [2]. Regional and Channel Insights - Revenue from mainland China increased by 9% year-on-year to 4.936 billion yuan, driven by strong growth in adult nutrition and care products and rapid channel expansion. Cross-border e-commerce revenue grew by 18%, with Douyin channel revenue surging by 80%, becoming a key growth engine [3]. - Revenue from Australia and New Zealand decreased by 18% to 801 million yuan, primarily due to a decline in corporate purchasing business [3]. - North American revenue increased by 6% to 862 million yuan, benefiting from the popularity of premium pet nutrition products and a growing pet population, with major retailers like Amazon, Walmart, and PerSmart performing well [3]. - Other regions saw a 17% year-on-year revenue increase to 420 million yuan, with strong growth in the Asian expansion market [3].

Core Viewpoint - H&H International Holdings reported a total revenue of 7.019 billion yuan for H1 2025, reflecting a 5% year-on-year increase, with adjusted comparable EBITDA of 1.101 billion yuan, down 3% year-on-year, and adjusted comparable net profit of 363 million yuan, up 5% year-on-year. The company is expected to see EPS of 0.79, 1.05, and 1.30 yuan for 2025-2027, with a "Buy" investment rating assigned by Huaxin Securities [1]. Revenue and Profitability - The company achieved a gross margin increase of 2 percentage points to 62.53% in H1 2025, driven by improved margins in adult and pet nutrition and care products, along with product mix optimization [1]. - The proportion of sales and distribution/administrative expenses to revenue increased by 3 percentage points and decreased by 0.4 percentage points to 42.33% and 5.68%, respectively, due to changes in the channel mix for adult nutrition and care products in mainland China and investments in new market expansion strategies [1]. - Adjusted comparable EBITDA margin and adjusted comparable net profit margin decreased by 1 percentage point and 0.02 percentage points to 15.68% and 5.17%, respectively, primarily due to high base effects from the previous year and increased selling expenses [1]. Business Segment Performance - In H1 2025, revenue from adult nutrition and care products increased by 5% to 3.439 billion yuan, largely due to the outstanding performance of Swisse's innovative anti-aging product line, which saw a 39% growth compared to the benchmark [2]. - Revenue from infant nutrition and care products rose by 3% to 2.501 billion yuan, supported by effective e-commerce channel development and educational initiatives for new mothers in specialty stores, with the product successfully transitioning to new national standards [2]. - Revenue from pet nutrition and care products increased by 10% to 1.079 billion yuan, with gross margin rising by 12 percentage points to 58.70%, driven by deepened North American channel cooperation and the ongoing high-end upgrade of Solid Gold in mainland China [2]. Regional and Channel Insights - Revenue from mainland China in H1 2025 grew by 9% to 4.936 billion yuan, primarily due to strong growth in adult nutrition and care products and rapid channel expansion, with cross-border e-commerce revenue increasing by 18% and Douyin channel revenue surging by 80% [3]. - Revenue from Australia and New Zealand decreased by 18% to 801 million yuan, mainly due to a decline in corporate purchasing business [3]. - North American revenue increased by 6% to 862 million yuan, benefiting from the popularity of high-end pet nutrition products and the growing pet population, with major retailers like Amazon and Walmart performing well [3]. - Other regions saw a revenue increase of 17% to 420 million yuan, with strong growth in the Asian expansion market [3].

Investment Rating - The report rates the health supplement industry as "Outperform" [1] Core Insights - The health supplement industry is entering a new upward cycle, driven by rising health awareness among younger consumers and the emergence of new consumption trends [6][9] - The market for nutritional health products in China is projected to reach 522.3 billion yuan by 2024, with a compound annual growth rate of 5.7% from 2019 to 2024 [10][11] - Online sales channels are becoming increasingly important, with a significant rise in sales through platforms like Douyin, which has become the leading online sales platform for health supplements [32][35] Summary by Sections Industry Characteristics - The industry is characterized by a clear trend towards younger consumers, the emergence of new niche markets, and accelerated product iteration [7][9] - The overall scale of the traditional health supplement market is over 300 billion yuan, growing at approximately 5% annually, while new consumption segments such as anti-aging and cardiovascular health are emerging [9] Market Dynamics - The online sales of health supplements in China grew from 107.4 billion yuan in 2022 to 142.1 billion yuan in 2023, indicating a strong shift towards e-commerce [29][30] - Douyin's sales growth in health supplements reached 38% in the first half of 2025, surpassing other platforms like Tmall and JD [32] Key Segments - The report identifies several high-growth segments within the health supplement industry: - Anti-aging: Focused on products like ergothioneine and NAD+ [49][52] - Sports nutrition: Emphasizing glucosamine and calcium products [55] - Cardiovascular health: Highlighting deep-sea fish oil and phospholipid products [58] - Liver health: Addressing needs arising from unhealthy lifestyles [61] - Probiotics: Targeting gut health and overall wellness [66] Investment Recommendations - The report suggests focusing on brands with strong product operation capabilities and high brand recognition, such as Ruoyuchen and H&H International Holdings [5][69] - For production, it recommends selecting leading companies with substantial scale and customer resources, such as Xianle Health [5][69] - In the raw material sector, it highlights industry leaders like Jindawei [5][69]

Core Insights - H&H Group's strategic adjustments, forward-looking layout, and solid financial foundation provide new possibilities for navigating cycles [1] - The company reported a 5.2% year-on-year revenue growth to 7.02 billion yuan in the first half of 2025, with the Chinese market contributing significantly [1][2] - The adult nutrition care (ANC) segment achieved revenue of 3.44 billion yuan, growing 5.9% year-on-year, while the pet nutrition care (PNC) segment grew 8.6% to 1.08 billion yuan [1][5] Revenue Breakdown - The Chinese market accounted for 70.3% of total revenue, with an 8.7% year-on-year growth [1] - ANC revenue was 3.44 billion yuan, BNC (infant nutrition and care) revenue was 2.50 billion yuan (up 2.9%), and PNC revenue was 1.08 billion yuan [1][5] - Swisse brand in the ANC segment saw a 13.1% growth in China, becoming the market leader [2][4] Market Trends - The global nutrition and health industry is undergoing adjustments amid declining population dividends and increasing competition [2] - H&H Group's focus on family nutrition has positioned it as a leader in the industry [2] - The demand for high-end infant formula is rising, with BNC segment revenue growing 10% in the Chinese market, significantly outperforming the overall market growth of 0.2% [8] Product Innovation - H&H Group is expanding its product offerings under the "mega brand" strategy, including high-end brands like SwissePlus and Little Swisse [3] - The company is responding to the growing demand for innovative anti-aging solutions, achieving significant breakthroughs in high-margin anti-aging supplements [3] Geographic Expansion - H&H Group's ANC business has seen growth in overseas markets, with Swisse becoming the top brand in Australia for vitamins and supplements [4] - The PNC segment is also growing steadily, with Solid Gold in China achieving a 17.5% growth rate [5][6] Financial Performance - The company recorded a gross profit of 4.389 billion yuan, a 7.8% increase year-on-year, with a gross margin improvement from 60.9% to 62.5% [10][11] - Cash reserves exceeded 18.3 billion yuan, supported by strong profit performance and efficient working capital conversion [12] - The company is actively refinancing to improve debt conditions and reduce overall financing costs [12]

I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01112 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD 100,000,000 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名 ...